mva85a
Vaccineexperimental
Clinical trial activity
23 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
19
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2002 (NCT00423566)
Timeline
Indications
Mechanism of action
- Mycobacterium tuberculosisImmunity, active
Mycobacterium tuberculosis immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aeras 485
- aeras-485
- mva85a
- mva85a
- mva 85a
- mva-85a
- mva ag85a
- mva-ag85a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03681860 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2018 | Medical Research Council-UVRI Uganda Research Unit on AIDS, University of London, University of Oxford |
| NCT02532036 | Phase 1 | Sep 1, 2015 | University of Birmingham, University of London, University of Oxford |
| NCT02178748 | Phase 2 | Jun 1, 2014 | Medical Research Council, University of Oxford |
| NCT01954563 | Phase 1 | Oct 1, 2013 | University of Oxford |
| NCT01829490 | Phase 1 | Jul 1, 2013 | University of Birmingham, University of Oxford |
| NCT01683773 | Phase 1 | Sep 1, 2012 | Aeras, Crucell, Emergent BioSolutions, University of Birmingham, University of Oxford |
| NCT01497769 | Phase 1 | Sep 1, 2011 | University of Oxford |
| NCT01151189 | Phase 2 | Jul 1, 2011 | Aeras, European and Developing Countries Clinical Trials Partnership (EDCTP), Hopital Aristide Le Dantec, University of Cape Town, University of Oxford |
| NCT01194180 | Phase 1 | May 1, 2010 | University of Oxford |
| NCT01181856 | Phase 1 | Jan 1, 2010 | University of Oxford |
| NCT00953927 | Phase 2 | Jul 1, 2009 | Aeras, South African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, University of Oxford |
| NCT00731471 | Phase 1 | Aug 1, 2008 | Centre Hospitalier Universitaire Le Dantec, University of Oxford |
| NCT00679159 | Phase 2 | Feb 1, 2008 | University of Cape Town, University of Oxford |
| NCT00480558 | Phase 1 | Jul 1, 2007 | University of Cape Town, University of Oxford |
| NCT00395720 | Phase 1 | Nov 1, 2006 | University of Oxford |
| NCT00480454 | Phase 1 | Oct 1, 2006 | Medical Research Council, University of Oxford |
| NCT00460590 | Phase 1 | Oct 1, 2005 | University of Cape Town, University of Oxford |
| NCT00465465 | Phase 1 | Oct 1, 2005 | University of Oxford |
| NCT00456183 | Phase 1 | Aug 1, 2005 | University of Oxford |
| NCT00427453 | Phase 1 | Jun 1, 2003 | University of Oxford |
Showing 20 of 23 trials
Page 1 / 2
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Oxford | Academic/Hospital | 23 | 21 | 2 | 2002 |
| University of Cape Town | Academic/Hospital | 5 | 0 | 2 | 2005 |
| Aeras | Academic/Hospital | 3 | 2 | 2 | 2009 |
| University of Birmingham | Academic/Hospital | 3 | 0 | 1 | 2012 |
| Medical Research Council | Government | 2 | 0 | 2 | 2006 |
| University of London | Academic/Hospital | 2 | 0 | 2 | 2015 |
| Centre Hospitalier Universitaire Le Dantec | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Crucell | For profit | 1 | 0 | 1 | 2012 |
| Emergent BioSolutions | For profit | 1 | 0 | 1 | 2012 |
| European and Developing Countries Clinical Trials Partnership (EDCTP) | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Hopital Aristide Le Dantec | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Medical Research Council-UVRI Uganda Research Unit on AIDS | Academic/Hospital | 1 | 0 | 1 | 2018 |
| South African Tuberculosis Vaccine Initiative (SATVI) | Academic/Hospital | 1 | 0 | 1 | 2009 |
13 organizations
Page 1 / 1